Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16130319 | 0.85 | ALDH1A1 (0.33) | ALDH1A1TSHRTP53TDP1CD44 | |
| SCHEMBL20169602 | 0.82 | CXCR5 (0.37) | ALDH1A1TSHRTP53TDP1CYP1A2 | |
| SCHEMBL41438 | 0.81 | ALDH1A1 (0.39) | ALDH1A1TSHRTP53TDP1CD44 | |
| SCHEMBL30332485 | 0.81 | ALDH1A1 (0.39) | ALDH1A1TSHRTP53TDP1CD44 | |
| SCHEMBL16130441 | 0.81 | CYP2A6 (0.39) | ALDH1A1TSHRTDP1CD44CYP1A2 | |
| Ethane SCHEMBL29184984 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRTP53TDP1CD44 | |
| SCHEMBL6469766 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRTP53TDP1CD44 | |
| SCHEMBL28553928 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRTP53TDP1CD44 | |
| Butadiene SCHEMBL10623583 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRTP53TDP1CYP1A2 | |
| SCHEMBL7921184 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546174-B2 | Inhibitor of apoptosis protein (IAP) antagonists | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-01-17 | — | — | US | disclosed |
| US-9434747-B2 | Methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150307499-A1 | INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2015-10-29 | — | — | US | disclosed |
| US-20140228353-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2012015760-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228353-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | ALDH1A1 1402/4885TSHR 97/4885TP53 4145/4885 |
| US-20150307499-A1 | INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS | API5, XIAP, BIRC5 | ALDH1A1 4556/4885TSHR 4620/4885TP53 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.